Redefining
Regenerative
Medicine

Histogen is a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body. This innovative technology utilizes human proteins and growth factors produced by hypoxia-induced multipotent cells to address what Histogen believes to be underserved, multibillion dollar global markets.

ABOUT

clinical programs

Histogen is advancing three clinical programs in therapeutic indications with large commercial market opportunities:

HAIR GROWTH

Hair Growth

A minimally-invasive treatment that is intended to grow new hair, not simply preserve existing hair.

 
SKIN CARE

Dermal Fillers

Human-derived collagen and extracellular matrix dermal fillers delivering potentially longer-lasting effects with fewer side effects for the treatment of facial folds and wrinkles.

 
MATRIX REGENERATION

Joint Cartilage Repair

Histogen’s extracellular matrix for articular cartilage defects regenerates hyaline cartilage for the treatment of knee osteoarthritis with a novel malleable scaffold produced by the body’s own stem cells.

 

Latest News

July 30, 2020
Histogen to Report Second Quarter 2020 Earnings on August 13, 2020

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that

Read more
July 29, 2020
Histogen to Present at the Canaccord Genuity 40th Annual Growth Conference

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that

Read more
July 20, 2020
Histogen Inc. Announces Common Stock Purchase Agreement for up to $10 Million with Lincoln Park Capital Fund, LLC

Includes an Initial Investment of $1 Million SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (“Histogen” or the “Company”) (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, today announced that it has that

Read more
View All